As reported, about one month post-implant of bard/davol ventralex st mesh, the patient was diagnosed with small area of fibrinous healing tissue and was treated with medication.As reported, the ae has resolved.The clinician has assessed the patient¿s postoperative course as being ¿possibly¿ related to the study device and definitely related to the index procedure, however, based on the information provided, no conclusion can be made.Not returned - remains implanted.
|
Reported per clinical trial (b)(6): on (b)(6) 2016 - subject patient underwent a primary open laparotomy midline umbilical hernia (1.5cm x 2.5 cm) repair procedure during which a bard/davol ventralex st was placed in underlay fashion in an intra-peritoneally and was fixated using suture.The fascia and full skin closure was achieved using sutures and adhesive skin closure.The patient was discharged on (b)(6) 2016.On (b)(6) 2016 - fibrinous healing tissue and was prescribed with application of sulfasalazine topically for 1-2 weeks until fully healed.On (b)(6) 2017 - the ae is resolved.Per the study clinician, the reported adverse event has been assessed as moderate in severity, possibly related to the study device and definitely related to the index procedure.The outcome for this ae is reported as recovered/resolved.
|